Telix Pharmaceuticals Limited (TLX) M&A Call Transcript

Telix Pharmaceuticals Limited ( TLX ) M&A Call September 20, 2026 7:30 PM EDT Company Participants Kyahn Williamson - Senior Vice President of Corporate Communications & Investor Relations Christian Behrenbruch - Co-Founder, MD, Group CEO & Executive Director Andrew Cavey - CEO & Member of the Executive Board Darren Smith - Group Chief Financial Officer Conference Call Participants Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Chris Cooper - JPMorgan Chase & Co, Research Division David Bailey - Morgan Stanley, Research Division Presentation Kyahn Williamson Senior Vice President of Corporate Communications & Investor Relations Good morning and good evening, everybody, and thank you so much for joining us today to discuss the announcement we made a short time ago regarding the merger of Telix and ITM. If we could just move to the next slide, please. Before we get into the official proceedings, I just have a few short disclaimers to read to you. This presentation contains forward-looking statements regarding our proposed transaction with the shareholders of ITM and expectations for ITM-11. These statements are subject to substantial risks, including, but not limited to, the outcome of the FDA's review following NDA resubmission, clinical trial results, regulatory approvals required in multiple jurisdictions and our ability to realize projected synergies. Actual results may differ materially. You are cautioned not to rely on these forward-looking statements, which are made only as of today's date. Please refer to the risk factors across our ASX and SEC filings and the legal section noted in this announcement and the ASX and the full disclaimer of your materials. With that, let us move into the official proceedings. So I'm very pleased to be welcome today by Dr. Christian Behrenbruch, the Managing Director and CEO of Telix Pharmaceuticals, along with Dr. Andrew Cavey, CEO of ITM; and Darren Smith, Group Chief Financial Officer of Telix. We will run through some formal remarks and then move